Ocugen
Get Full AccessDescription
- Ocugen, Inc. is a rapidly growing, clinical stage biopharmaceutical company dedicated to developing innovative therapies and novel biologics for rare and underserved ocular disorders. Ocugen is aggressively pursuing new treatments for ocular graft versus host disease (OCU300), dry eye disease (OCU310), retinitis pigmentosa (OCU100) and wet AMD (OCU200). Our lead programs OCU300 and OCU310 are being developed through the FDAs 505(b)(2) pathway and expected to enter pivotal clinical trials in 2018. In addition, OCU300 received the first and only orphan drug designation for ocular graft versus host disease from the Food and Drug Administration (FDA) providing certain regulatory and economic benefits. For more information, please visit www.ocugen.com.
-
Headquarters:5 Great Valley Parkway , Malvern, Pennsylvania, United States
More -
Phone Number: +1 484-328-4701
-
Website: https://www.ocugen.com
-
Employees:15
-
Revenue:$10 - 50M
-
Legal Name:Ocugen
-
Ocugen's Social Media
-
Is this data correct?
-
| NAICS Code: 446110 |
Show More
Sell more in less time!
Buyer intent data, anonymous visitor identification, first party data integration backed by a massive contact database that will supercharge your sales team. Schedule a demo to learn more!
Frequently Asked Questions regarding Ocugen
-
Where are Ocugen's Headquarters?
Ocugen's Headquarters are in 5 Great Valley Parkway ,Malvern,Pennsylvania,United States
-
What is Ocugen's phone number?
Ocugen's phone number is +1 484-328-4701
-
What is Ocugen's official website?
Ocugen's official website is https://www.ocugen.com
-
What is Ocugen's Revenue?
Ocugen's revenue is $10 - 50M
-
What is Ocugen's NAICS code?
Ocugen's NAICS code is 446110
-
How many employees are working in Ocugen
Ocugen has 15 employees
-
What is Ocugen's Industry?
Ocugen is in the industry of Biotechnology
-
Who is Ocugen's CEO?
Ocugen's CEO is Shankar Musunuri